Washington Post Health Brief on Thursday July 9: 'The Peptide Showdown' — Reporter Megan R. Wilson Sustains the Mainstream-Media Coverage Wave With a Second WaPo Beat in Ten Days on the FDA Career-Staff Versus RFK Jr. Tension Two Weeks Before the July 23-24 PCAC Vote, Extending the Newspaper's June 30 'Peptides Are Popular and Controversial. Why?' Explainer Framework
The Washington Post Health Brief published Thursday July 9, 2026 a column by reporter Megan R. Wilson titled 'The peptide showdown,' sustaining WaPo's coverage of the FDA compounding-peptide review through a second full policy-newsletter beat in 10 days. The column extends the framework established in WaPo's June 30 general-audience explainer 'Peptides Are Popular and Controversial. Why?' The July 9 piece keeps the newspaper's mainstream-media pressure focused on the tension between FDA career scientists (June 29-30 briefing documents concluding all seven peptides have insufficient evidence for 503A eligibility) and HHS Secretary RFK Jr.'s public push to expand peptide compounding access. Combined with NPR's July 8 nationally syndicated feature ('What's behind the push to make peptide therapies more readily available'), the two consecutive mainstream-outlet beats push the panel-composition and evidence-base story past trade press (Endpoints, STAT, FiercePharma) and into general-audience awareness heading into the July 23-24 vote at White Oak.